JP4314113B2 - ヘパラン硫酸プロテオグリカンに対する標的化のための、ニューレグリンヘパリン結合ドメインとのハイブリッドタンパク質 - Google Patents

ヘパラン硫酸プロテオグリカンに対する標的化のための、ニューレグリンヘパリン結合ドメインとのハイブリッドタンパク質 Download PDF

Info

Publication number
JP4314113B2
JP4314113B2 JP2003517223A JP2003517223A JP4314113B2 JP 4314113 B2 JP4314113 B2 JP 4314113B2 JP 2003517223 A JP2003517223 A JP 2003517223A JP 2003517223 A JP2003517223 A JP 2003517223A JP 4314113 B2 JP4314113 B2 JP 4314113B2
Authority
JP
Japan
Prior art keywords
polypeptide
receptor
nucleic acid
cell
hbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003517223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500052A5 (enExample
JP2005500052A (ja
Inventor
ジェフリー エー． ローブ，
Original Assignee
ウェイン・ステイト・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェイン・ステイト・ユニバーシティ filed Critical ウェイン・ステイト・ユニバーシティ
Publication of JP2005500052A publication Critical patent/JP2005500052A/ja
Publication of JP2005500052A5 publication Critical patent/JP2005500052A5/ja
Application granted granted Critical
Publication of JP4314113B2 publication Critical patent/JP4314113B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003517223A 2001-07-31 2002-07-31 ヘパラン硫酸プロテオグリカンに対する標的化のための、ニューレグリンヘパリン結合ドメインとのハイブリッドタンパク質 Expired - Fee Related JP4314113B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30856301P 2001-07-31 2001-07-31
PCT/US2002/024053 WO2003012045A2 (en) 2001-07-31 2002-07-31 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans

Publications (3)

Publication Number Publication Date
JP2005500052A JP2005500052A (ja) 2005-01-06
JP2005500052A5 JP2005500052A5 (enExample) 2006-06-15
JP4314113B2 true JP4314113B2 (ja) 2009-08-12

Family

ID=23194471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517223A Expired - Fee Related JP4314113B2 (ja) 2001-07-31 2002-07-31 ヘパラン硫酸プロテオグリカンに対する標的化のための、ニューレグリンヘパリン結合ドメインとのハイブリッドタンパク質

Country Status (8)

Country Link
US (1) US7527794B2 (enExample)
EP (1) EP1456239B1 (enExample)
JP (1) JP4314113B2 (enExample)
AT (1) ATE427317T1 (enExample)
AU (1) AU2002322762B2 (enExample)
CA (1) CA2455830C (enExample)
DE (1) DE60231833D1 (enExample)
WO (1) WO2003012045A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005271902B2 (en) * 2004-07-09 2011-12-08 Wayne State University Hybrid proteins with erbB4 extracellular domain and neuregulin heparin-binding domain for targeting
US20110034383A1 (en) * 2007-10-15 2011-02-10 Institut Pasteur Cxcl12 gamma a chemokine and uses thereof
EP2346526A2 (en) * 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2011147981A2 (en) * 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
US8961981B2 (en) 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2020142587A1 (en) 2019-01-03 2020-07-09 The Board Of Trustees Of The University Of Illinois Method and kit for treating a neurodegenerative disease
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8947791A (en) * 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
WO1994008007A1 (en) 1992-09-29 1994-04-14 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JP2000510879A (ja) 1995-09-05 2000-08-22 ケンブリッジ ニューロサイエンス，インコーポレイテッド 特異的なオリゴ糖−ニューレグリン相互作用のためのアナログおよびその使用
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
ATE290595T1 (de) * 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
WO1998043649A2 (en) 1997-03-28 1998-10-08 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
AU4469997A (en) * 1997-09-17 1999-04-05 Urs Eppenberger Heregulin-gamma
GB2363714B (en) 1998-04-23 2004-03-03 Vladimir Leko Herbal composition and medicament against diabetes mellitus type II manufactured thereof
CA2325919C (en) * 1999-01-29 2009-07-21 Kaneka Corporation Processes for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives

Also Published As

Publication number Publication date
EP1456239A4 (en) 2005-04-27
AU2002322762B2 (en) 2008-10-16
CA2455830A1 (en) 2003-02-13
US20050107601A1 (en) 2005-05-19
WO2003012045A3 (en) 2004-07-01
ATE427317T1 (de) 2009-04-15
US7527794B2 (en) 2009-05-05
EP1456239A2 (en) 2004-09-15
DE60231833D1 (de) 2009-05-14
EP1456239B1 (en) 2009-04-01
CA2455830C (en) 2012-10-09
JP2005500052A (ja) 2005-01-06
WO2003012045A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
JP3039802B2 (ja) 繊維芽細胞成長因子のための受容体
Funakoshi et al. Identification of Gas6, a putative ligand for Sky and Axl receptor tyrosine kinases, as a novel neurotrophic factor for hippocampal neurons
US7341996B2 (en) Processed vascular endothelial growth factor-B polypeptides
JP3595552B2 (ja) ヘレグリンの構造、生産および用途
RU2477287C2 (ru) Стабилизированные полипептиды инсулиноподобного фактора роста
US20030114658A1 (en) Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
JPH11507332A (ja) 結合組織成長因子
PL212078B1 (pl) Modyfikowany propeptyd BMP-11, jego zastosowanie i sposób wytwarzania, kodująca go cząsteczka kwasu nukleinowego, zawierające je kompozycje farmaceutyczne oraz rekombinowana komórka
JPH11509187A (ja) 内皮細胞増殖の調節
EP1456239B1 (en) Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
JP2003159083A (ja) 新規な神経栄養因子
JP2002505078A (ja) 血管内皮増殖因子の可溶性インヒビターおよびその使用
AU2002322762A1 (en) Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
US20090088375A1 (en) Human prolactin antagonist-angiogenesis inhibitor fusion proteins
JP2008539745A (ja) エリスロポエチン変異体
JP4955548B2 (ja) 標的化のためのＥｒｂＢ４細胞外ドメインおよびニューレグリンヘパリン結合ドメインを有するハイブリッドタンパク質
US7534436B2 (en) Peptide fragments of the harp factor inhibiting angiogenesis
WO2005053729A1 (en) Stem cell factor for inducing neural stem cell migration to areas of neurological injury
JPH05229957A (ja) Ｍｋタンパク質
Sanderson et al. Heregulin (HRG)-induced Mitogenic Signaling and Cytotoxic Activity of a HRG/PE4O Ligand Toxin in Human Breast Cancer Cells’
JPH05213771A (ja) ヘパリン結合性神経突起の成長プロモーター因子
Chen et al. Development of Novel Activin-Targeted
MXPA98003767A (en) Receivers of the neurotrophic factor derived from cell line gl
MXPA99010773A (en) Glial cell line-derived neurotrophic factor receptors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090501

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090518

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120522

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130522

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees